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ISSNObjective: HIV infection is characterized by several immune dysfunctions, such as
chronic activation of the immune system, premature aging and loss of CD4þ T cells, in
particular within the naı̈ve compartment. The Tat protein of HIV is released extracellu-
larly and enters neighboring cells affecting their functionality, for instance impacting on
CD8þ T-cell programs and activity. As the presence and/or induction of anti-Tat
immune responses is associated with reduced T-cell dysfunction and CD4þ T-cell loss,
we investigated whether Tat impacts human resting or activated CD4þ T cells.
Methods: Purified CD4þ T cells were activated by T cell receptor engagement in the
presence or absence of Tat. Cytokine production, surface phenotype and expression of
transcription factors important for T-cell programing were measured. Purified naı̈ve
CD4þ T cells were cultured in nonpolarizing conditions in the presence or absence of
Tat and their proliferation and differentiation was evaluated.
Results: Tat favors the secretion of IL2, IFNg and TNFa in CD4þ T cells, as well as the
upregulation of T-bet and Eomes expression. Naı̈ve CD4þ T cells cultured in the
presence of Tat showed enhanced expansion and differentiation toward memory
phenotype, showing in particular recruitment into the effector memory T-cell pool.
Conclusion: Tat affects the programing and functionality of CD4þ T lymphocytes
favoring the differentiation of naı̈ve CD4þ T cells.
Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2018, 32:575–581Keywords: CD4þ, HIV, immune activation, Tat, T-cell programing Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
e Sciences and Biotechnology, University of Ferrara, Ferrara, bDepartment of Molecular Medicine, University of
taly, cDepartment of Immunology, NIMR Mbeya Medical Research Centre, Mbeya, Tanzania, dDivision of
s and Tropical Medicine, Medical Center of the University of Munich (LMU), eGerman Center for Infection
artner Site Munich, Munich, Germany, and fNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
o Prof. Riccardo Gavioli, PhD, Department of Life Sciences and Biotechnology, University of Ferrara, Via
64A, 44121 Ferrara, Italy.
407; fax: +39 0532974408; e-mail: r.gavioli@unife.it
2017; revised: 3 November 2017; accepted: 17 November 2017.
.0000000000001734
0269-9370 Copyright Q 2018 Wolters Kluwer Health, Inc. All rights reserved. 575
576 AIDS 2018, Vol 32 No 5Introduction
HIV infection strongly affects cellular immunity, causing
the depletion of CD4þ T cells, in particular within the
naı̈ve compartment [1], and dysfunction of both CD8þ
and CD4þ T lymphocytes [2–6]. This status of chronic
immune dysregulation involves the whole T-cell com-
partment, including uninfected T cells [7], and is not
completely restored during effective antiretroviral therapy
(ART). There is a general consensus on the complexity of
these phenomena which seem to be due not only to viral
replication and CD4þ T cells loss, but also to the
immunomodulatory activity of HIV products, including
Tat [5,7]. Indeed, the HIV-1 Tat protein is released
extracellularly [8], even during ART [9], and enters
neighboring cells affecting their functionality [10–15]. In
this context, it has been shown that Tat has a strong
impact on CD8þ T-cell programs and activity [15] and,
in murine models, favors the activation of CD8þ T cells
and the modulation of antiviral responses [16], causing
dysfunctions similar to those observed in HIV-infected
individuals. It is also noteworthy that naturally acquired
or vaccine-induced anti-Tat immunity limits T-cell
dysfunction, CD4þ T-cell loss and viral load, and is
associated with the reduction of proviral DNA, resulting
in the delay of disease progression [17–21]. However,
whether Tat has a direct or indirect effect upon the CD4þ
T-cell compartment is currently unknown. To shed light
on this issue, we have determined whether extracellular
bioactive Tat impacts human resting or activated CD4þ
T cells. Our results show that Tat promotes the activation
of CD4þ T cells as well as differentiation of naı̈ve CD4þ
T cells toward memory subtypes that may result in the
generation of new targets of infection.Materials and methods
Human cells and culture conditions
Buffy coats from healthy volunteers, who provided
consent, were obtained from the University Hospital of
Ferrara. Peripheral blood lymphocytes (PBLs) were
separated by use of Ficoll–Hypaque (Lonza, Basel,
Switzerland) density gradient centrifugation followed
by 90 min of adhesion on a plastic support at 37 8C to
remove monocytes.
Total and naı̈ve CD4þ T cells were sorted by MACS
magnetic selection (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to manufacturer’s instructions and
cultured, as detailed in Supplemental information, http://
links.lww.com/QAD/B210, in the absence or presence
of the Tat protein in 24-well flat-bottomed polystyrene
plates precoated overnight at 4 8C with PBS or anti-
CD3 mAb (0.5 mg/ml; R&D Systems, Minneapolis,
Minnesota, USA). Naı̈ve CD4þ T cells were cultured in
nonpolarizing condition as previously described [22] and Copyright © 2018 Wolters Kluwer Hdetailed in Supplemental information, http://links.lww.
com/QAD/B210.
Tat protein
HIV-1 Tat from human T lymphotropic virus type IIIB
isolate (BH10 clone) was expressed in Escherichia coli and
purified by heparin-affinity chromatography and HPLC,
as described previously [10]. The lyophilized Tat protein
was then stored at 80 8C and handled as described [10].
Endotoxin concentration was below the detection limit
(0.05 EU/mg).
Flow cytometry
Surface and intracellular staining were performed as
detailed in Supplemental information, http://links.lww.
com/QAD/B210.
Gene-expression analysis
Gene expression was evaluated by quantitative as detailed
in Supplemental information, http://links.lww.com/
QAD/B210.Results
Tat enhances CD4R T-cell activation
The HIV-1 Tat protein, which is released by infected
cells, enhances the production of proinflammatory
cytokines from activated PBLs and CD8þ T cells
[15,23,24]. To understand whether soluble Tat, at
physiological concentration within a nanomolar range,
may induce cytokine production in CD4þ T cells, resting
or anti-CD3/CD28-stimulated T helper lymphocytes
from healthy donors were cultured for 4 h in the absence
or presence of 0.1 mg/ml of Tat protein. As shown in
Fig. 1a, Tat significantly increased the expression of IL2,
IFNg and TNFa mRNAs in anti-CD3/CD28-stimu-
lated CD4þ T cells, but not in resting lymphocytes. This
effect was observed at similar levels for Tat doses ranging
from 0.01 to 1 mg/ml, and it was abolished after
incubation with anti-Tat positive sera (Fig. S1, http://
links.lww.com/QAD/B210). This result was confirmed
by cytokine intracellular staining of the cells that
demonstrated increased production of IL2, IFNg and
TNFa (Fig. 1b) after 18 h of treatment with Tat when
compared with untreated cells. However, the expression
of early (CD69) and late (CD25, CD38, HLA-DR)
activation markers was not affected by the presence of Tat
(Fig. S2, http://links.lww.com/QAD/B210). As these
results indicate that, in human-activated CD4þ T cells,
Tat enhances the production of Th1-type cytokines,
which are under the control of T-box transcription factors
[25,26], we characterized the expression of T-bet and
Eomes in resting and activated CD4þ T cells cultured in
the absence or in the presence of Tat. As shown in Fig. 1c,
Tat did not induce the mRNA expression of T-box
transcription factors in unstimulated CD4þ T cells,ealth, Inc. All rights reserved.
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

































































































































































Fig. 1. Tat favors CD4R T-cell activation. CD4þ T cells purified from healthy donors (n¼7) unstimulated or activated with anti-
CD3/CD28 were cultured in the absence or presence of soluble Tat (0.1 mg/ml). After 4 h, IL2, IFNg, TNFa (a), T-bet and Eomes (c)
mRNA levels were quantified by qPCR and normalized to untreated cells. (b) Peripheral blood lymphocytes from healthy donors
(n¼3–7) unstimulated or activated with anti-CD3/CD28 were cultured in the absence or presence of 0.1 mg/ml of Tat. After 18 h,
IL2, IFNg and TNFa production was measured by intracellular cytokine staining in CD4þ T cells. Dots represent single donors and
lines represent the median. For statistical analysis, two-tailed Wilcoxon signed-rank test was used. P<0.05: Tat-treated activated
cells compared with Tat-untreated activated control cells. qPCR, quantitative
578 AIDS 2018, Vol 32 No 5whereas it increased significantly the expression of T-bet
and Eomes transcription factors in CD3/CD28-activated
CD4þ T cells as compared with CD4þ T cells activated
with CD3/CD28 and cultured in the absence of Tat.
Thus, at a physiological concentration, soluble Tat
protein enhances the production of proinflammatory
cytokines in activated CD4þ T cells and influences the
expression of transcription factors crucial for T-cell
programing and functionality.
Tat favors the expansion and the differentiation
of naı̈ve CD4R T cells
The HIV-related chronic immune activation plays
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Fig. 2. Tat affects homeostasis of naı̈ve CD4R T cells. Purified naı̈ve
absence or presence of 0.1 mg/ml of soluble Tat. (a) Cell number was e
donor out of seven (a1) and means SEM of data normalized to day 0
by flow cytometry at 12 and 18 days of culture. One representati
means SEM of data normalized to baseline levels (b2) are shown (
were calculated at 18 days of culture. Data from seven healthy don
signed-rank test was used. P< 0.05: Tat-treated cells compared widifferentiation of naı̈ve T cells into memory cells
[1,27] leading to a decline of naı̈ve T cells. As our data
clearly indicate that Tat favors the activation of CD4þ T
cells and the expression of transcription factors control-
ling T-cell programing, we wondered whether Tat had
also an effect upon proliferation and differentiation
of naı̈ve lymphocytes, thus participating in immune
activation and pathogenesis of HIV infection. To address
this, purified naı̈ve CD4þ T cells were cultured, in the
presence or absence of Tat, in nonpolarizing conditions
(NPC) to induce their activation and differentiation
toward a memory phenotype avoiding potential biases
due to polarization toward some specific T helper cell

























































CD4þ T cells from healthy donors were cultured in NPC in the
valuated along thecourse of thecell culture. One representative
(a2) are shown (n¼7). (b) Expression of CD45RA was evaluated
ve donor out of seven (b1, expressed as histogram plot) and
n¼7). (c) Percentages of different CD4þ T-cell subpopulations
ors are presented. For statistical analysis, two-tailed Wilcoxon
th Tat-untreated control cells. NPC, nonpolarizing conditions.
Tat induces CD4R T-cell activation Nicoli et al. 579the proliferation of naı̈ve CD4þT cells starting from day 7
and reaching the peak at day 12. The addition of Tat
enhanced duration and magnitude of naı̈ve T helper cell
expansion which peaked at day 15 and remained higher
until day 18. To determine whether Tat affected the
differentiation of naı̈ve CD4þ T cells cultured in NPC,
the phenotype of T helper lymphocytes was assessed.
Overall, NPC prompted the loss of CD45RA expression
(Fig. 2b), suggesting a shift toward a nonnaı̈ve phenotype
that had started by day 12, with a more pronounced
downregulation by day 18. Significantly, this phenome-
non was more pronounced in the presence of Tat. In
fact, higher numbers of central memory (CD45RA,
CCR7þ, CD27þ), transitional memory (CD45RA,
CCR7, CD27þ) and effector memory (CD45RA,
CCR7, CD27) CD4þ T cells were generated in the
presence of Tat as compared with NPC alone (Fig. 2c). It
is noteworthy that effector memory CD4þ T cells were
almost absent in cultures derived from naı̈ve CD4þT cells
activated under NPC, whereas they were strongly
induced in the presence of Tat (Fig. 2c). Taken together,
these data suggest that Tat supports the activation of naı̈ve
CD4þ T cells promoting their transition toward more
differentiated phenotypes.Discussion
The Tat protein of HIV is released by infected cells [8] and
interacts with neighboring cells [10–15]. We showed
here that soluble Tat favors the activation of CD4þT cells
inducing the release of proinflammatory cytokines and
the expression of transcription factors such as T-bet and
Eomes which are crucial for T-cell activation and
differentiation. In addition, Tat increased the expansion
and differentiation of naı̈ve CD4þ T cells activated in
NPC. These findings, together with the observations
made in CD8þ T cells [15,16,28], confirm that Tat plays
an important role in the hyperactivation of the T-cell
compartment, a phenomenon characterizing the pro-
gression to AIDS and possibly the residual disease
observed in successfully ART-treated individuals [29,30].
Naı̈ve CD4þ T cells are resistant to productive HIV
infection due to their quiescent state [31,32]. However,
their number dramatically decreases during AIDS [1], in
part due to the status of chronic immune activation which
favors their differentiation into memory and effector cells
[27,33]. Tat, by favoring naı̈ve T-cell activation, promotes
their recruitment into the memory compartment and,
fostering the exit from a quiescent state, might also
contribute to the generation of new potential targets of
infection, in line with previous observations showing
higher susceptibly to HIV infection by CD4þ T cells
exposed to Tat [34,35]. Tat expression has been detected
in tissues from patients on ART [36], whose success is
dependent on the levels of naı̈ve CD4þ T cells [37], a
compartment not always fully reconstituted by ART [29]. Copyright © 2018 Wolters KluweTherefore, our data suggest that blocking Tat effects may
favor therapy efficacy, as indeed observed in ART-treated
individuals vaccinated with the Tat protein that showed
restored T-cell responses against heterologous antigens
and a rise in CD4þ T-cell count [18,19].
In previous works conducted with cell lines, Tat was
alternatively shown to promote apoptosis or to have
antiapoptotic effects, for instance promoting the release
of IL2 [38–40]. On primary human CD4þ T cells, Tat
immobilized on solid support, but not high concentrations
of soluble Tat, was shown to mediate IL2 production
[41,42]. In contrast, we showed here that soluble Tat, used
at physiological concentrations [43], induced IL2 produc-
tion in primary human CD4þ T cells. Thus, our data
would argue against a direct effect of Tat on T-cell death as
the main mechanism of CD4þ T-cell depletion.
Tat does not promote the exit from a quiescent state of
resting lymphocytes, thus probably not affecting viral
reservoirs [44]. However, in activated T helper lympho-
cytes, it favors the production of IL2, IFNg and of TNFa,
whose plasmatic levels are increased in HIV-infected
individuals [45,46]. Significantly, loss of naı̈ve T cells,
accumulation of differentiated lymphocytes and an
increased level of proinflammatory cytokines are hall-
marks of the accelerated immunosenescence characteriz-
ing HIV-infected individuals [47–49]. Our data suggest
that Tat may support this phenomenon through the
induction of proinflammatory cytokines and differentia-
tion of T cell receptor-stimulated naı̈ve CD4þ T cells
toward late stages of differentiation, such as effector
memory T cells. Accordingly, Tat has been shown to
induce production of IL6 [50], which is associated with
immunosenescence [51], reduction of telomerase activity
in CD4þ T cells [52] and senescence of bone marrow
mesenchymal stem cells [53].
In conclusion, our data suggest that Tat may contribute
to the exacerbation of several immune dysfunctions
observed during AIDS progression, such as chronic
immune activation and premature aging. Therefore, the
induction of anti-Tat immune responses by Tat adminis-
tration can be an effective strategy for restoration of the
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